SCHEMBL7597985

SCHEMBL7597985

CC(C)(C)C1Cc2cc(N3C[C@H](COS(C)(=O)=O)OC3=O)ccc2N1C(=O)OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 13/20 0.38
MAOB P27338 2/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
DRD1 P21728 1/20 0.35
HRH2 P25021 1/20 0.35
HTR1B P28222 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR1E P28566 1/20 0.35
SLC6A4 P31645 1/20 0.35
HRH1 P35367 1/20 0.35
HTR2B P41595 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MAOA P21397 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6956015 0.89 MAOB (0.44) GRM2MAOBHTR1AADRA2AADRA2B
SCHEMBL6961334 0.88 GRM2 (0.40) GRM2MAOBHTR1AADRA2AADRA2B
SCHEMBL6972550 0.88 GRM2 (0.38) GRM2MAOBHTR1AADRA2AADRA2B
SCHEMBL6963698 0.84 F10 (0.43) MAOBMAOA
SCHEMBL6963692 0.84 F10 (0.43) MAOBMAOA
SCHEMBL6208617 0.81 NPC1 (0.42) GRM2HTR1AADRA2AADRA2BADRA2C
SCHEMBL5326969 0.80 MAOB (0.51) MAOBMAOA
SCHEMBL6961081 0.78 MAOB (0.41) GRM2MAOBMAOA
SCHEMBL6964490 0.78 MAOA (0.46) GRM2MAOBHTR1AADRA2AADRA2B
SCHEMBL27458038 0.78 MAOA (0.46) GRM2MAOBHTR1AADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020143009-A1 Novel bicyclic oxazolidinones as antibacterial agents PHARMACIA & UPJOHN 2002-10-03 US disclosed
US-6387896-B1 GRAMNEGATIVE, GRAMPOSITVE BACTERIA PHARMACIA & UPJOHN CO. 2002-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143009-A1 Novel bicyclic oxazolidinones as antibacterial agents OXA1L, MRPL21, RPS4Y1 GRM2 4081/4885MAOB 1600/4885HTR1A 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.